Daiichi Sankyo Company, Limited (DSKYF) Stock

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited operates as a global pharmaceutical powerhouse, dedicated to the research, development, manufacturing, and worldwide commercialization of a wide array of medicinal products. The company boasts an extensive portfolio of therapeutics spanning numerous health conditions. In oncology, its offerings include trastuzumab deruxtecan, an innovative anti-HER2 antibody-drug conjugate for cancer treatment, alongside agents such as gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen for breast cancer. For chronic diseases, Daiichi Sankyo provides mirogabalin for pain management; treatments for type 2 diabetes mellitus like teneligliptin/canagliflozin and teneligliptin; and medications for hypercholesterolemia, including pravastatin and colesevelam (which also addresses type 2 diabetes). Bone health is supported by denosumab for osteoporosis and related conditions, while anemia is managed with ferric carboxymaltose and iron sucrose injections. Its cardiovascular and neurological solutions include the antiplatelet agent prasugrel, the anticoagulant edoxaban, and the antihypertensive olmesartan; as well as lacosamide for epilepsy and memantine for Alzheimer's disease. Other key prescription products address conditions such as ulcers (esomeprazole), influenza (laninamivir), bacterial infections (levofloxacin), dysuria (silodosin), and general pain and inflammation (loxoprofen). Beyond prescription drugs, Daiichi Sankyo also markets a selection of consumer health items. These comprise the multi-symptom cold remedy Lulu, the antipyretic/anti-inflammatory pain reliever Loxonin S, Transino for skin discoloration like melasma and freckles, Minon skincare products, and the oral hygiene brands Breath Labo and Clean Dental. Furthermore, the company produces various vaccines, including those for influenza (both cell culture-derived and HA types), measles, rubella, and mumps. Its diverse operations extend to veterinary pharmaceuticals, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and chemical intermediates. A significant collaboration involves Guardant Health, with whom Daiichi Sankyo is developing Guardant360 CDx as a companion diagnostic for Enhertu, specifically targeting advanced metastatic non-small cell lung cancer. Established in 1899, this long-standing organization is headquartered in Tokyo, Japan.

Daiichi Sankyo Company, Limited is headquartered in JP.

Daiichi Sankyo Company, Limited (DSKYF) stock trades at $17.40 with a market capitalization of $31.66B. The stock is valued at a price-to-earnings (P/E) ratio of 21.23, price-to-book of 3.00, price-to-sales of 2.30. Over the past 52 weeks the stock has ranged between $13.85 and $29.15, and currently trades 40.3% below its 52-week high. It pays a dividend yielding 3.62%.

On profitability, Daiichi Sankyo Company, Limited generates a return on equity (ROE) of 14.44%, above the typical market average, return on capital employed of 5.86%, an operating margin of 8.83%, a net profit margin of 10.93%.

In its most recent fiscal year, Daiichi Sankyo Company, Limited reported annual revenue of $2.14T, net profit of $261.5B, revenue has compounded at 17.3% a year over the last five years, profit at 28.1% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.29 — a conservative balance sheet with little leverage risk, a current ratio of 2.92, total assets of $4.03T, $452.6B in cash and equivalents.

DSKYF has an average daily trading volume of 10,320 shares, a beta of 0.12 (less volatile than the overall market).

Official website: www.daiichisankyo.com